Christopher Reinhard - Taxus Cardium CEO
| CRXMDelisted Stock | USD 0.0001 0.00 0.00% |
CEO
Mr. Christopher J. Reinhard is Chairman of the Board, President, Chief Executive Officer, Treasurer of Taxus Cardium Pharmaceuticals Group Inc. Mr. Reinhard has played a leadership role in the preclinical, clinical and commercial development of the Generx program. In 1996, he was cofounder of Collateral Therapeutics, which licensed the Generx technology covering methods of cardiovascular gene therapy based on discoveries by researchers at the University of California, San Diego. He helped lead a five year strategic partnership with Schering AG that supported the clinical development of Generx and ultimately led Schering to purchase Collateral for approximately 160 Million. After Schering was subsequently acquired by Bayer, Mr. Reinhard and Dr. DylanHyde cofounded Cardium Therapeutics to reacquire rights to the technology and advance the Generx program as a nonsurgical approach to the treatment of coronary heart disease. He is also Chief Executive Officer and President of Tissue Repair Company, a whollyowned subsidiary of Cardium, since August 2006. He served as a director and Chief Executive Officer of Cardiums subsidiary InnerCool Therapies Inc., from its acquisition in March 2006 until sale of the business to Royal Philips Electronics in July 2009 and its subsidiary To Go Brands Inc., from its acquisition in September 2012 until sale of the business to CellNique Corporation in November 2013. Previously, he served as a director and the Chief Executive Officer, President and Treasurer of Aries Ventures Inc. from October 20, 2005 through its merger with Cardium in January 2006. Mr. Reinhard received a B.S. in Finance and an M.B.A. from Babson College. Mr. Reinhard is a cofounder and serves as an inside director and the Chairman of our Board of Directors. He has significant industry experience as well as public company experience. since 2003.
| Age | 69 |
| Tenure | 21 years |
| Professional Marks | MBA |
| Phone | 858 414 1477 |
| Web | https://genebiotherapeutics.com |
Taxus Cardium Management Efficiency
The company has return on total asset (ROA) of (2.619) % which means that it has lost $2.619 on every $100 spent on assets. This is way below average. Taxus Cardium's management efficiency ratios could be used to measure how well Taxus Cardium manages its routine affairs as well as how well it operates its assets and liabilities.Taxus Cardium Pharmaceuticals currently holds 1.26 M in liabilities. Taxus Cardium Pharma has a current ratio of 0.08, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Taxus Cardium until it has trouble settling it off, either with new capital or with free cash flow. So, Taxus Cardium's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Taxus Cardium Pharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Taxus to invest in growth at high rates of return. When we think about Taxus Cardium's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 6 records | CEO Age | ||
| Markus MD | Monte Rosa Therapeutics | 53 | |
| John MBA | Akebia Ther | 60 | |
| Robert Coffin | Replimune Group | 59 | |
| Kathryn MBA | Blueprint Medicines Corp | 48 | |
| Steven MD | Sana Biotechnology | 54 | |
| Mark Goldsmith | Revolution Medicines | 62 | |
Management Performance
| Return On Asset | -2.62 |
Taxus Cardium Pharma Leadership Team
Elected by the shareholders, the Taxus Cardium's board of directors comprises two types of representatives: Taxus Cardium inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Taxus. The board's role is to monitor Taxus Cardium's management team and ensure that shareholders' interests are well served. Taxus Cardium's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Taxus Cardium's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ronald Shebuski, Chief Officer | ||
| Christopher Reinhard, Co-Founder, CEO and President Treasurer and Executive Director | ||
| Lois Chandler, Chief Officer | ||
| Duane Linstrom, G Counsel | ||
| James Grainer, CFO Chairman | ||
| Kelly Scott, VP Inc |
Taxus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Taxus Cardium a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -2.62 | |||
| Current Valuation | 881.11 K | |||
| Shares Outstanding | 64.93 M | |||
| Shares Owned By Insiders | 0.21 % | |||
| Number Of Shares Shorted | 150.25 K | |||
| Price To Book | 3.36 X | |||
| Price To Sales | 137.13 X | |||
| EBITDA | (458.68 K) | |||
| Net Income | (517.9 K) | |||
| Cash And Equivalents | 386.03 K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Other Consideration for investing in Taxus Pink Sheet
If you are still planning to invest in Taxus Cardium Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Taxus Cardium's history and understand the potential risks before investing.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |